Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 6, 2013, Pages 483-492

  Wang, B ^a   Higgs, B W ^a   Chang, L ^a   Vainshtein, I ^a   Liu, Z ^a   Streicher, K ^a   Liang, M ^a   White, W I ^a   Yoo, S ^a   Richman, L ^a   Jallal, B ^a   Roskos, L ^a   Yao, Y ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BIOLOGICAL MARKER; INTERFERON; MEDI 546; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG INDICATION; DRUG SCREENING; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; MULTIPLE CYCLE TREATMENT; NAUSEA; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACOGENETICS; RECEPTOR, INTERFERON ALPHA-BETA; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84878228166     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.35     Document Type: Article

References (51)

1. Theoflopoulos, A.N., Baccala, R., Beutler, B. & Kono, D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
2. Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H. & Schreiber, R.D. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
3. Pestka, S. The human interferon alpha species and receptors. Biopolymers 55, 254-287 (2000).
4. Biron, C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 14, 661-664 (2001).
5. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
6. Niewold, T.B., Rivera, T.L., Buyon, J.P. & Crow, M.K. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum. 58, 541-546 (2008).
7. Baechler, E.C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100, 2610-2615 (2003).
8. Greenberg, S.A. et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57, 664-678 (2005).
9. van der Pouw Kraan, T.C. et al. Rheumatoid arthritis subtypes identifed by genomic profling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 66, 1008-1014 (2007).
10. Farina, G., Lafyatis, D., Lemaire, R. & Lafyatis, R. A four-gene biomarker predicts skin disease in patients with difuse cutaneous systemic sclerosis. Arthritis Rheum. 62, 580-588 (2010).
11. Assassi, S. et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 62, 589-598 (2010).
12. Hjelmervik, T.O., Petersen, K., Jonassen, I., Jonsson, R. & Bolstad, A.I. Gene expression profling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum. 52, 1534-1544 (2005).
13. Higgs, B.W. et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70, 2029-2036 (2011).
14. Hooks, J.J., Moutsopoulos, H.M., Geis, S.A., Stahl, N.I., Decker, J.L. & Notkins, A.L. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301, 5-8 (1979).
15. Lahita, R.G. Systemic Lupus Erythematosus, 3rd edn (Academic Press, San Diego, CA, 1999).
16. Kammer, G.M. & Tsokos, G.C. Lupus: Molecular and Cellular Pathogenesis (Humana Press, Totowa, NJ, 1999).
17. Hua, J., Kirou, K., Lee, C. & Crow, M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54, 1906-1916 (2006).
18. Pascual, V., Farkas, L. & Banchereau, J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol. 18, 676-682 (2006).
19. Yao, Y. et al. Neutralization of interferon-alpha/beta-inducible genes and downstream efect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60, 1785-1796 (2009).
20. Han, G.M., Chen, S.L., Shen, N., Ye, S., Bao, C.D. & Gu, Y.Y. Analysis of gene expression profles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 4, 177-186 (2003).
21. Fleming, J.N. et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3, e1452 (2008).
22. Coelho, L.F. et al. Increased expression of 2'5'oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on afected skin of systemic sclerosis patients. Arch. Dermatol. Res. 299, 259-262 (2007).
23. Tan, F.K. et al. Signatures of diferentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford). 45, 694-702 (2006).
24. Duan, H. et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profles in patients with scleroderma. Arthritis Rheum. 58, 1465-1474 (2008).
25. Beretta, L., Caronni, M., Vanoli, M. & Scorza, R. Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br. J. Dermatol. 147, 385-386 (2002).
26. Ioannou, Y. & Isenberg, D.A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43, 1431-1442 (2000).
27. Solans, R., Bosch, J.A., Esteban, I. & Vilardell, M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin. Exp. Rheumatol. 22, 625-628 (2004).
28. Crow, M.K. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 36, 173-186, x (2010).
29. York, M.R., Nagai, T., Mangini, A.J., Lemaire, R., van Seventer, J.M. & Lafyatis, R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum. 56, 1010-1020 (2007).
30. Tannous, B.A., Kim, D.E., Fernandez, J.L., Weissleder, R. & Breakefeld, X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 11, 435-443 (2005).
31. Bengtsson, A.A. et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9, 664-671 (2000).
32. Dall'era, M.C., Cardarelli, P.M., Preston, B.T., Witte, A. & Davis, J.C. Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 64, 1692-1697 (2005).
33. von Wussow, P., Jakschies, D., Hartung, K. & Deicher, H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol. Int. 8, 225-230 (1988).
34. Kirou, K.A. et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50, 3958-3967 (2004).
35. Coelho, L.F., de Oliveira, J.G. & Kroon, E.G. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma? Immunol. Lett. 118, 110-115 (2008).
36. Eloranta, M.L. et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann. Rheum. Dis. 69, 1396-1402 (2010).
37. Bilgic, H. et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 60, 3436-3446 (2009).
38. Feng, X. et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2951-2962 (2006).
39. Baechler, E.C. et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol. Med. 13, 59-68 (2007).
40. Yao, Y. et al. Development of potential pharmacodynamic and diagnostic markers for Anti-IFN-a monoclonal antibody trials in systemic lupus erythematosus. Hum. Genomics Proteomics 2009, 374312 (2009).
41. Yao, Y., Higgs, B.W., Richman, L., White, B. & Jallal, B. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNa antibody, in systemic lupus erythematosus. Arthritis Res. Ther. 12 (suppl. 1), S6 (2010).
42. Merrill, J.T. et al.; Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profle and clinical activity of sifalimumab, a fully human antiinterferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70, 1905-1913 (2011).
43. Paquet, P., Kaveri, S., Jacob, E., Pirson, J., Quatresooz, P. & Piérard, G.E. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp. Dermatol. 15, 381-386 (2006).
44. Oh, C.K. et al. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br. J. Clin. Pharmacol. 69, 645-655 (2010).
45. Tabrizi, M. et al. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with infammatory diseases. Infamm. Allergy Drug Targets 9, 229-237 (2010).
46. DiMasi, J.A. & Grabowski, H.G. Economics of new oncology drug development. J. Clin. Oncol. 25, 209-216 (2007).
47. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010).
48. Yao, Y. et al. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 3, e2737 (2008).
49. Holford, N.H. The Visual Predictive Check-Superiority to Standard Diagnostic (Rorschach) Plots. 14th meeting of the Population Approach Group in Europe, Pamplona, Spain, 16-17 July 2005.
50. Ette, E.I. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37, 486-495 (1997).
51. Lindbom, L., Pihlgren, P., Jonsson, E.N. & Jonsson, N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed efect modeling using NONMEM. Comput. Methods Programs Biomed. 79, 241-257 (2005).